Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer

Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer
Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. The trial, which included 23 evaluable patients with either recurrent platinum-resistant ovarian cancer or platinum-sensitive disease, found that

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *